Asundexian Cuts Risk of Second Stroke - Results from OCEANIC-STROKE
Автор: HCPLive
Загружено: 2026-02-05
Просмотров: 81
Описание:
Asundexian, an investigational oral Factor XIa (FXIa) inhibitor in development by Bayer, has shown its superiority to placebo in preventing ischemic stroke in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA), based on results from the pivotal phase 3 OCEANIC-STROKE trial. We spoke with Andrew Russman, DO, neurologist and section head of stroke and vascular neurology at the Cleveland Clinic, to learn more.
“I think it’s really important to recognize that we’re always concerned that we’re adding bleeding risk. But that was not the case with asundexian in this study. Essentially, patients benefitted by a reduction in their ischemic stroke risk without a concomitant increase in bleeding risk. And this is critically important."
Key Timestamps
00:00:01 Intro
00:00:07 Overview of OCEANIC-STROKE
00:03:54 Why FXIa Inhibitors Can Outperform Traditional Anticoagulation
00:05:12 Subgroup analysis of asundexian
00:07:10 FXIa Receptors' Place in the Cascade
00:08:37 Addressing Skepticism About Separating Thrombosis from Hemostasis
Read more at https://www.hcplive.com/view/oceanic-...
#cardiology #stroke
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
